Congolese Health Minister Kamba said on the 27th that in response to the current Ebola outbreak, the country officially launched Ervebo vaccination on the same day in Kisangani, the capital of the eastern province of Chopo. The first batch of vaccinations included frontline workers such as healthcare workers. The current outbreak in the Congo was caused by the Bendibujo Ebola virus. Currently, there is no vaccine or specific treatment for this type of virus. The Ervebo vaccine, which has been approved to prevent the Zairian Ebola virus, is not clear about the human protective effect of Bendibujo Ebola virus. However, early laboratory and animal experimental data suggest that the Ervebo vaccine may have some protective effect. Kamba said at the launch ceremony on the same day that the Congo decided to use the Ervebo vaccine to give priority protection to frontline healthcare workers and people who have had contact with Ebola patients. African Center for Disease Prevention and Control official Yap Boom said at an online press conference on the 27th that the vaccination was carried out under the framework of “compassionate use according to the plan” and that relevant data will be collected to assess the actual impact of the Ervebo vaccine on the current outbreak. Boom said that up to now, the Congo has received 16,520 doses of the Ervebo vaccine. The World Health Organization issued a communiqué on the 20th saying that the International Coordination Group for Vaccine Supply has notified the Congolese government that it will immediately allocate the first batch of 70,000 doses of the Ervebo vaccine, 20,000 of which will be used to conduct phase 3 clinical trials to evaluate the protective effects of the vaccine against Bendibujo Ebola virus; 50,000 doses will be used for frontline workers and health workers. According to data released by the Ministry of Health of the Congo on the 27th, as of the 25th, the country had reported a cumulative total of 5,713 confirmed cases, including 2,744 deaths and 1,269 cured cases; the case fatality rate was 48%.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.